We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
Read MoreHide Full Article
Key Takeaways
ISRG is leveraging da Vinci 5 data, AI and connected workflows to drive future growth.
ISRG aims to use AI for anatomy identification, guidance and workflow optimization.
ISRG's 1,500 da Vinci 5 systems and 3M annual procedures fuel a growing data moat.
Intuitive Surgical’s (ISRG - Free Report) next growth frontier may not be a new robotic platform but the digital ecosystem being built around its installed base. During the first quarter of 2026, management outlined a long-term strategy centered on leveraging surgical data, artificial intelligence and connected workflows to enhance outcomes and further differentiate the da Vinci franchise.
At the core of this strategy is a powerful data flywheel. The company highlighted that the da Vinci 5 platform captures surgical video, robotic kinematic data, force-feedback information and clinical context from connected electronic medical records. By combining these datasets, Intuitive Surgical aims to gain deeper insights into procedural variation, workflow efficiency and patient outcomes. Management believes these proprietary datasets provide a unique competitive advantage that becomes stronger as procedure volumes and installed systems grow.
The first wave of AI applications is expected to focus on decision support and workflow optimization. Management described AI-enabled anatomy identification, tissue-plane visualization and guidance tools that could assist surgeons during procedures. Beyond the operating room, AI-driven analytics may help hospitals improve robotic program efficiency, utilization and cost management.
Intuitive Surgical is pursuing a path toward more advanced capabilities, including augmented dexterity, camera automation and other forms of surgical assistance. The company also reaffirmed that telesurgery remains on its roadmap, building on growing adoption of My Intuitive+ and telepresence tools that already support mentoring, proctoring and remote collaboration among surgeons.
The scale of data gathered from its wide base of hardware is likely to create a moat for Intuitive Surgical, giving it an advantage over emerging competitors. With approximately 1,500 da Vinci 5 systems in the field and more than three million annual procedures across its ecosystem, the company is continuously generating real-world datasets that competitors cannot easily replicate. Management believes this expanding repository of surgical intelligence can create a self-reinforcing advantage, enabling better AI models, stronger clinical insights and more differentiated products over the next three to five years.
Peer Update
Abbott (ABT - Free Report) is also building a technology moat by combining proprietary devices, digital health platforms and clinical evidence across multiple care pathways. In diabetes care, Abbott’s Libre ecosystem remains a key differentiator, with management estimating a long-term opportunity of 70-80 million patients globally and expanding use cases through upcoming dual-analyte glucose-ketone monitoring and future sensor innovations. Beyond diabetes, Abbott is strengthening its moat through advanced electrophysiology technologies, including newly launched pulsed field ablation (PFA) catheters, the AVEIR leadless pacing platform and next-generation structural heart devices. The acquisition of Exact Sciences further enhances Abbott’s competitive position by adding integrated cancer diagnostics capabilities, creating a broader data, diagnostics and medical technology ecosystem that competitors may find difficult to replicate.
Boston Scientific (BSX - Free Report) is creating a durable competitive moat through a combination of differentiated technologies, clinical evidence generation and integrated treatment ecosystems. The strongest example is FARAPULSE, where Boston Scientific continues to expand beyond a single catheter into a comprehensive electrophysiology platform that includes OPAL mapping, FARAVIEW imaging, Farapoint and future-generation ablation technologies. In the structural heart, Boston Scientific is reinforcing the WATCHMAN franchise through large-scale clinical studies such as CHAMPION, aiming to expand patient eligibility and strengthen physician adoption. The company is also building moats in interventional oncology, intravascular lithotripsy and neuromodulation through proprietary devices, software-enabled workflows and long-term outcomes data. Together, these technology platforms create switching costs, support premium pricing and help Boston Scientific maintain leadership positions in several high-growth medical device markets.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 27.2% so far this year compared with a 15.2% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 37.65, above the industry average. But it is still lower than its five-year median of 70.02. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 16.5% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
Can ISRG's Digital Roadmap Unlock the Next Phase of Robotic Surgery?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) next growth frontier may not be a new robotic platform but the digital ecosystem being built around its installed base. During the first quarter of 2026, management outlined a long-term strategy centered on leveraging surgical data, artificial intelligence and connected workflows to enhance outcomes and further differentiate the da Vinci franchise.
At the core of this strategy is a powerful data flywheel. The company highlighted that the da Vinci 5 platform captures surgical video, robotic kinematic data, force-feedback information and clinical context from connected electronic medical records. By combining these datasets, Intuitive Surgical aims to gain deeper insights into procedural variation, workflow efficiency and patient outcomes. Management believes these proprietary datasets provide a unique competitive advantage that becomes stronger as procedure volumes and installed systems grow.
The first wave of AI applications is expected to focus on decision support and workflow optimization. Management described AI-enabled anatomy identification, tissue-plane visualization and guidance tools that could assist surgeons during procedures. Beyond the operating room, AI-driven analytics may help hospitals improve robotic program efficiency, utilization and cost management.
Intuitive Surgical is pursuing a path toward more advanced capabilities, including augmented dexterity, camera automation and other forms of surgical assistance. The company also reaffirmed that telesurgery remains on its roadmap, building on growing adoption of My Intuitive+ and telepresence tools that already support mentoring, proctoring and remote collaboration among surgeons.
The scale of data gathered from its wide base of hardware is likely to create a moat for Intuitive Surgical, giving it an advantage over emerging competitors. With approximately 1,500 da Vinci 5 systems in the field and more than three million annual procedures across its ecosystem, the company is continuously generating real-world datasets that competitors cannot easily replicate. Management believes this expanding repository of surgical intelligence can create a self-reinforcing advantage, enabling better AI models, stronger clinical insights and more differentiated products over the next three to five years.
Peer Update
Abbott (ABT - Free Report) is also building a technology moat by combining proprietary devices, digital health platforms and clinical evidence across multiple care pathways. In diabetes care, Abbott’s Libre ecosystem remains a key differentiator, with management estimating a long-term opportunity of 70-80 million patients globally and expanding use cases through upcoming dual-analyte glucose-ketone monitoring and future sensor innovations. Beyond diabetes, Abbott is strengthening its moat through advanced electrophysiology technologies, including newly launched pulsed field ablation (PFA) catheters, the AVEIR leadless pacing platform and next-generation structural heart devices. The acquisition of Exact Sciences further enhances Abbott’s competitive position by adding integrated cancer diagnostics capabilities, creating a broader data, diagnostics and medical technology ecosystem that competitors may find difficult to replicate.
Boston Scientific (BSX - Free Report) is creating a durable competitive moat through a combination of differentiated technologies, clinical evidence generation and integrated treatment ecosystems. The strongest example is FARAPULSE, where Boston Scientific continues to expand beyond a single catheter into a comprehensive electrophysiology platform that includes OPAL mapping, FARAVIEW imaging, Farapoint and future-generation ablation technologies. In the structural heart, Boston Scientific is reinforcing the WATCHMAN franchise through large-scale clinical studies such as CHAMPION, aiming to expand patient eligibility and strengthen physician adoption. The company is also building moats in interventional oncology, intravascular lithotripsy and neuromodulation through proprietary devices, software-enabled workflows and long-term outcomes data. Together, these technology platforms create switching costs, support premium pricing and help Boston Scientific maintain leadership positions in several high-growth medical device markets.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 27.2% so far this year compared with a 15.2% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 37.65, above the industry average. But it is still lower than its five-year median of 70.02. ISRG carries a Value Score of F.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 16.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.